Neos Therapeutics Profit Margin

The latest profit margin for NEOS is -38.35% as of September 2020. That compares with -35.99% in the prior-year period — down 6.6% year over year. That is below the Healthcare sector average of 15.29%. Investors often review this figure alongside Neos Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, NEOS's profit margin moved from -35.99% to -38.35% — a 6.6% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Neos Therapeutics's valuation or profitability profile.

Against Healthcare companies, NEOS currently prints -38.35% for profit margin, while the sector average sits near 15.29%. That is roughly 350.8% below the sector mean. Large gaps often invite a closer look at Neos Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Neos Therapeutics converts resources into returns. At -38.35%, NEOS may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -35.99% in the prior-year period — down 6.6% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting NEOS's profit margin (-38.35%), review year-over-year change from -35.99%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.